 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper128th MAINE LEGISLATURE
FIRST REGULAR SESSION-2017
Legislative Document No. 1619
H.P. 1118 House of  Representatives, May 23, 2017
An Act  To Report Limited  Information to the Controlled 
Substances Prescription Monitoring Program Concerning Methadone
Reported by Representative HYMANSON of York for the Joint Standing Committee on 
Health and Human Services  pursuant to Joint Order  2017, H.P. 946.
Reference to the Committee on Health  and Human Services suggested and  ordered printed 
pursuant to Joint Rule 218.
ROBERT  B. HUNT
Clerk

 
 Page 1 - 128LR2337(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  5 MRSA §20047, sub -§3 is enacted to read:  2 
3.  Medical emergency; methadone.  Notwithstanding subsection 1, records relating 3 
to methadone treatment of a patient for the treatment of opio id dependency that have been 4 
entered into the Controlled Substances Prescription Monitoring Program established 5 
under Title 22, section 7248 may be disclosed in an emergency setting only to the extent 6 
necessary to meet a bona fide medical emergency in whic h the patient's prior informed 7 
consent cannot be obtained and only to the health care professionals involved in treating 8 
the patient.  Any disclosure of records pursuant to this subsection must be documented as 9 
described in Title 22, section 7250, subsecti on 7.  10 
Sec. 2.  22 MRSA §7249 -A is enacted to read:  11 
§7249 -A.  Reporting of methadone treatment with consent  12 
1.  Consent form; methadone treatment.  The department shall develop a consent 13 
form to be presented to a patient who begins receiving methadone treat ment at any 14 
facility that provides methadone for the treatment of opioid dependency.  The form 15 
records the patient's identifying information along with consent to enter the name of the 16 
patient's methadone treatment facility and dosage information into the program. The 17 
contents of the form may be disclosed only in a medical emergency as described in 18 
section 7250, subsection 7.  The patient may decline consent.  19 
2.  Treatment facility to enter information into the program.  For a patient who 20 
has provided conse nt pursuant to subsection 1, a prescriber at a facility that provides 21 
methadone for the treatment of opioid dependency shall enter the patient's identifying 22 
information along with the name of the methadone treatment facility and the dosage 23 
information into  the program every 90 days.  If a patient ceases treatment or moves to a 24 
different facility, the patient's methadone treatment facility must notify the program 25 
within 30 days of such change in status.  26 
3.  Renewal of consent form.  A facility that provides methadone for the treatment 27 
of opioid dependency must provide a new consent form under subsection 1 to a patient 28 
annually and renew that patient's consent.  The patient may choose to decline consent or 29 
void consent at any time.  30 
Sec. 3.  22 MRSA §7250, sub -§7 is enacted to read:  31 
7.  Disclosure of methadone treatment in a medical emergency; documentation.  32 
Records entered pursuant to section 7249 -A may be disclosed in an emergency setting 33 
only to the extent necessary to meet a bona fide emergency in which the  patient's prior 34 
informed consent cannot be obtained and only to the health care professionals involved in 35 
treating the patient.  These records may not be disclosed in any other circumstances, 36 
including to prescribers using the program to enter or check in formation outside of the 37 
medical emergency.  Records disclosed pursuant to this subsection may not be used to 38 
initiate or substantiate any criminal charges against a patient or to conduct any criminal 39 
 
 Page 2 - 128LR2337(01) -1 
 investigation.  Any disclosure pursuant to this subsect ion is subject to the following 1 
requirements.  2 
A.  The disclosure must be documented by the health care professional involved in 3 
treating the patient and entered into the program and communicated to the patient's 4 
methadone treatment facility.  The documenta tion must include the date and time of 5 
the disclosure, the nature of the patient's emergency, the name of the facility or the 6 
hospital where the disclosure occurred and the names of the health care professionals 7 
who accessed the records.  8 
B.  Any disclosure  must include a statement that informs the health care professionals 9 
accessing the program that federal law prohibits the health care professionals from 10 
making further disclosures that identify the patient without the specific written 11 
consent of the patien t. 12 
Sec. 4.  Enhancement of the Controlled Substances Prescription 13 
Monitoring Program.  The Department of Health and Human Services shall submit a 14 
request for proposals pursuant to the Maine Revised Statutes, Title 22, section 7248, 15 
subsection 2 for an enha ncement of the Controlled Substances Prescription Monitoring 16 
Program under Title 22, chapter 1603. This enhancement must allow a facility that 17 
provides methadone for the treatment of opioid dependency to enter the name of the 18 
methadone treatment facility t reating a patient and the dosage information for a patient 19 
who has given consent.  The information may not be accessible except to health care 20 
professionals during an emergency to the extent necessary to meet a bona fide emergency 21 
in which the patient's pr ior informed consent cannot be obtained.  Any disclosure in an 22 
emergency setting must be entered into the program, including the date and time of the 23 
disclosure, the nature of the patient's emergency, the name of the facility or hospital 24 
where the disclosu re occurred and the names of the health care professionals who 25 
accessed the records in the program.  The enhancement of the program must be available 26 
no later than July 1, 2018 and must meet the requirements of Title 22, section 7250, 27 
subsection 7.  28 
Sec. 5.   Contingent effective date.  Those sections of this Act that enact the 29 
Maine Revised Statutes, Title 5, section 20047, subsection 3, Title 22, section 7249 -A 30 
and Title 22, section 7250, subsection 7 take effect once the enhancement of the 31 
Controlled Subst ances Prescription Monitoring Program pursuant to section 4 of this Act 32 
is implemented.  The Department of Health and Human Services shall notify the Revisor 33 
of Statutes that section 4 has been implemented.  34 
Sec. 6.  Consent form.  A facility that provides methadone for the treatment of 35 
opioid dependency must provide a consent form as described in the Maine Revised 36 
Statutes, Title 22, section 7249 -A for every patient no later than 180 days after the 37 
effective date of this Act.  38 
SUMMARY  39 
This bill allows for th e name of a methadone treatment facility and dosage 40 
information regarding methadone for the treatment of opioid dependency to be entered 41 
into the Controlled Substances Prescription Monitoring Program if a patient has given 42 
 
 Page 3 - 128LR2337(01) -1 
 consent to the facility and the i nformation is disclosed only during a medical emergency 1 
and only to medical personnel involved in treating the patient.  Any disclosure of 2 
methadone dosage information must be documented in the Controlled Substances 3 
Prescription Monitoring Program and comm unicated to the methadone treatment facility.  4 
 
